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Abstract 
The Mantel-Haenszel method has been used for decades to synthesize data obtained from studies that 
compare two interventions with respect to a binary outcome. It has been shown to perform better than 
the inverse-variance method or Peto’s odds ratio when data is sparse. Network meta-analysis (NMA) is 
increasingly used to compare the safety of medical interventions, synthesising for example data on 
mortality or serious adverse events. In this setting, sparse data occur often and yet there is to-date no 
extension of the Mantel-Haenszel method for the case of NMA. In this paper we fill this gap by 
presenting a Mantel-Haenszel NMA method for odds ratios. Similarly to the pairwise Mantel-Haenszel 
method, we assume common treatment effects. We implement our approach in R, and we provide freely 
available, easy-to-use routines. We illustrate our approach using data from two previously published 
networks. We compare our results to those obtained from three other approaches to NMA: NMA with 
non-central hypergeometric likelihood, an inverse-variance NMA and a Bayesian NMA with a binomial 
likelihood. We also perform simulations to assess the performance of our method and compare it with 
alternative methods. We conclude that our Mantel-Haenszel NMA method offers a reliable approach to 
the network meta-analysis of binary outcomes, especially in the case or sparse data, and when the 
assumption of methodological and clinical homogeneity is justifiable. 
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1 Introduction 
Meta-analysing studies with rare binary outcomes can be methodologically challenging, 
especially when some of the studies report zero events in one or both treatment arms. The inverse-
variance method, assuming a common-effects (“fixed-effects”) or random-effects1, is the most widely 
used approach to pairwise meta-analysis2. The method requires estimates of a relative treatment effect 
from each study along with a standard error. For the case of binary outcomes the approach employs 
approximations that do not perform well when event rates are low and/or the sample sizes of the included 
studies are small. If studies report zero events in one of their arms, the basic formulae cannot be used to 
estimate odds ratios, risk ratios and their standard errors because the calculations involve division by 
zero. A simple way to overcome this problem is to add a fixed number (e.g. 0.5) to the number of events 
and non-events of all treatment arms in studies that report zero events in one of their arms; studies with 
zero events in both arms are usually excluded from the analysis. This so-called ‘continuity correction’ 
bypasses the problem of zero events, and allows the use of the inverse variance method. However, it has 
been shown that this approach leads to bias in estimated effects3. Sweeting el al. suggested a flexible 
approach, where the continuity correction is adapted to each study, and showed that such corrections 
performed better than fixed ones4. However, the use of any type of continuity correction has been 
criticized because data are imputed and because the – essentially arbitrary – choice of the correction 
may bias results5,6.  
Another approach to address this problem is to use the risk difference instead of odds or risk 
ratios. The risk difference can readily be estimated in the presence of zero events. Unfortunately, as 
shown in simulations by Bradburn et al.3 “all risk difference methods yield very conservative confidence 
interval coverage when events are rare, and have associated poor statistical power, which make them 
unsuitable for meta-analysis of rare events”. Alternative methods have been  proposed, including the 
use of the arcsine difference7, an exact method combining confidence intervals8, beta-binomial models6 
etc; for a short review see a recent paper by Efthimiou9.  
The Mantel-Haenszel (MH) method is a popular approach to meta-analysing binary outcomes10. 
It has been formulated for the case of odds ratios, risk ratios and risk differences. Estimating MH odds-
ratios does not require a continuity correction for the case of studies with zero events in one of their 
arms, unless all studies in the dataset have zero events for the same treatment. Meta-analysis using the 
MH odds-ratio has been shown to outperform the inverse variance method when events are rare3. Note 
that using the MH method we exclude studies with zero events in all treatment arms. This has been 
criticised, because such studies may carry information through their sample size6. Another popular 
approach to meta-analysing rare binary outcomes is Peto’s odds ratio11. This method has been shown to 
work well when specific conditions are met (event rates are less than 1%, treatment groups are  balanced 
and relative effects are not very large) 3,4.  
 Network meta-analysis (NMA) is an extension of pairwise meta-analysis for the case when 
studies compare multiple treatments 12–16. The frequentist approaches that are usually employed for 
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fitting a NMA follow the inverse-variance method. Thus, they are expected to perform poorly when 
event rates are low. Bayesian approaches to NMA that utilize the exact binomial likelihood of the data17 
are also widely used18. However, when data are sparse, the choice of prior distributions for a Bayesian 
NMA becomes very important, and distributions that are thought to be “uninformative” or “vague” may 
strongly influence results19. This problem may be even more pronounced for the case of priors for 
heterogeneity in a random-effects meta-analysis20. Including informative priors in the analysis may help 
overcoming such issues. Stijnen et al. proposed an alternative approach to NMA of sparse data, based 
on a non-central hypergeometric function19. Higgins and Whitehead proposed an extension of Peto’s 
method for NMA21. This method, however, will have the same limitations as Peto’s pairwise meta-
analysis.  
In this paper we introduce a MH-NMA method for odds ratios, which can be of particular value 
when event rates are low. We implement our method in the netmeta package in R.  In order to illustrate 
our approach we re-analyze data from two previously published NMAs. We also perform simulations 
to assess the performance of our method in comparison with alternative NMA methods.  
2 Illustrative data from published networks 
In this section we briefly describe two datasets that we use to illustrate the methods we present in 
this paper.  
2.1 Inhaled medications for patients with chronic obstructive pulmonary disease 
The first dataset comes from a review that compared the safety of inhaled medications in patients 
with chronic obstructive pulmonary disease22. The outcome we focus on is mortality. The available data 
included 41 randomized trials, with a total of 52462 patients. Mortality was low, with 2408 deaths 
(4.6%) reported across all studies. There were nine studies that reported zero events in at least one of 
the treatment arms and three additional studies had zero events in all treatment arms (‘all-zero studies’). 
The network is depicted in the left panel of Figure 1. The data is given in Section 1 of the Appendix. 
2.2 Methods to decrease blood loss and blood transfusion requirements for patients with 
liver transplantation 
The second dataset comes from a review that compared methods for decreasing blood loss and 
blood transfusion requirements during liver transplantation23. The outcome we analyse is mortality at 
60 days post-transplantation. The network compared seven alternative methods. Fourteen studies 
reported mortality at 60 days, in 1002 patients. Forty-five deaths were reported across all studies (4.5%). 
Six studies observed deaths in all treatment arms while three studies did not observe any deaths. The 
network is depicted in the right panel of Figure 1. Note that one of the treatments in the original dataset 
(solvent detergent plasma) was only included in one study with zero events in all treatment arms (‘all-
zero study’). This treatment was excluded from the network graph.  
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Figure 1. a) inhaled medications in patients with chronic obstructive pulmonary disease. LABA: long-
acting β2 agonists. ICS: inhaled corticosteroids. TIO-HH: tiotropium dry powder; TIO-SMI: 
tiotropium solution. b) Methods to prevent blood loss in liver transfusion. EACA: Epsilon amino 
caproic acid; rFVIIa: recombinant factor VIIa. 
The thickness of the lines connecting the treatments is proportional to the inverse standard error of the 
corresponding treatment effects, based on a Mantel-Haenszel NMA. The numbers on the edges show 
the number of studies per comparison. 
 
3 Methods 
3.1 Mantel-Haenszel network meta-analysis method (MH-NMA) 
In this section we describe our method for network meta-analysis using MH odds ratios. The analysis 
is performed in three stages.  
Stage 1: setting up the data 
In the first stage we bring the data in an appropriate format for MH-NMA in five steps. 
i. We remove all-zero studies from the dataset. These studies contribute no information to the 
calculation of MH odds ratios. 
ii. We group studies by design. Here the word “design” is used to denote the treatments being 
compared in each study24. E.g. a study comparing treatments X and Y is of an XY design, a 
study comparing X, Y and Z is of an XYZ design, etc. 
iii. Within each design, we search for treatments for which all studies in the design reported zero 
events, and remove the treatments from the design. For example, if in all XYZW studies 
there were no events observed in arm Y, we remove the Y arms from these studies. These 
studies now include information only on X, Z and W. This is required because MH odds-
ratios cannot be estimated; however, the design will still be labelled as XYZW. We follow 
this approach aiming to be consistent with the original idea about how study design may 
interact with treatment effects24. Quoting from that paper, “…we implicitly assume that 
different designs (i.e. different sets of included treatments) may serve as a proxy for one or 
more important effect modifiers”. Note that all these relate to the way we later assess 
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inconsistency, see Section 3.2 below. Also note that instead of removing these treatment 
arms, we could use a continuity correction, but as discussed above, this strategy has 
important limitations. In our software implementation we allow both choices (see section 
4.1). 
iv. If designs are left with only one treatment arm after step (iii), we completely remove these 
designs from the data.   
v. We check the network connectivity. After steps (iii) and (iv) above, there is the chance that 
the network becomes disconnected (or completely disappear, if all designs are affected). In 
such cases a NMA cannot be performed in the whole dataset, but only in connected 
subnetworks.  
At the end of this first stage we have a new dataset, typically a subset of the original data, in which 
all studies are grouped by design 
Stage 2: Direct MH meta-analyses per design 
At the second stage we synthesise data within each design using the MH meta-analysis method.  
Note that a total of  𝑇𝑑(𝑇𝑑 − 1)/2  different log-odds ratios can be estimated from each design 𝑑, where 
𝑇𝑑 is the number of treatments in this design. For the NMA, however, we only need 𝑇𝑑 − 1 parameters 
to be estimated per design25. These parameters can be chosen to be the log-odds ratios of all treatments 
versus an arbitrary treatment in this design.  Thus, at the end of this stage, for each design 𝑑 we need to 
obtain a vector ?̂?(𝑑) of MH summary log-odds ratios with dimensions 1 × (𝑇𝑑 − 1) and the 
corresponding variance-covariance matrix 𝑽(𝑑). 𝑽(𝑑)is a symmetric matrix, with dimensionality (𝑇𝑑 −
1) × (𝑇𝑑 − 1). Following Lu et al. 
25, the summary information of this first stage of the analysis can be 
then written compactly as a vector 𝜽 = (?̂?(1) , ?̂?(2) , … , ?̂?(𝑁𝑑) ) and a matrix 𝑽 =
𝑑𝑖𝑎𝑔(𝑽(1), 𝑽(2), … , 𝑽(𝑁𝑑)), where 𝑁𝑑 is the number of different designs in the network. Thus, the 
dimensions of 𝜽 are 1 × ∑ (𝑇𝑑 − 1)𝑑  and the dimensions of  𝑽 are ∑ (𝑇𝑑 − 1)𝑑 × ∑ (𝑇𝑑 − 1)𝑑 . 
Estimation of ?̂?(𝑑) and 𝑽(𝑑) is standard when the design has only two arms (𝑇𝑑 = 2) and can be 
performed using already available software (e.g. metan26 in Stata or meta27 in R). For designs with more 
than two arms (𝑇𝑑 > 2) we employ a generalized MH estimator, as proposed by Greenland 
28. The details 
of this estimator are presented below.  
Let us assume that in design 𝑑 there are 𝑆𝑑 studies comparing 𝑇𝑑 different treatments. Assume 
that study 𝑖 provides data in the form of a (𝑇𝑑 × 2) table, as shown in Table 1. Following Greenland’s 
notation, we define 𝑐𝑋𝑌𝑖 = 𝑎𝑋𝑖𝑏𝑌𝑖/𝑡+𝑖 and 𝐶𝑋𝑌 = ∑ 𝑐𝑋𝑌𝑖
𝑆𝑑
𝑖=1 . In this notation, 𝐶𝑋𝑌/𝐶𝑌𝑋 corresponds to 
the usual MH estimator for the comparison X vs. Y, when 𝑇𝑑 = 2. Mickey and Elashoff suggested that 
this expression can also be used to estimate odds ratios for 𝑇𝑑 > 2
29. Greenland  provided an alternative 
estimator which he showed to have an efficiency advantage28, and this is what we will use here.  
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Study arm Events Non-events Total 
Treatment 𝑋 𝑎𝑋𝑖 𝑏𝑋𝑖 𝑡𝑋𝑖 
Treatment 𝑌 𝑎𝑌𝑖 𝑏𝑌𝑖 𝑡𝑌𝑖 
Treatment 𝑍 𝑎𝑍𝑖 𝑏𝑍𝑖 𝑡𝑍𝑖 
… … … … 
Total 𝑎+𝑖 𝑏+𝑖 𝑡+𝑖 
Table 1. Data available from study 𝑖, comparing treatments X, Y, Z, … 
 
For simplicity, and without loss of generality, let us consider treatment X to be the reference 
treatment for this design. Then, our goal is to estimate the 𝑇𝑑 − 1 summary MH log-odds ratios ?̂?(𝑑) =
(𝜃𝑑,𝑋𝑌, 𝜃𝑑,𝑋𝑍, … ) and their variance-covariance matrix 𝑽(𝑑). Let us define 𝐿𝑋𝑌 = ln (𝐶𝑋𝑌/𝐶𝑌𝑋), and 
𝑤𝑋𝑌𝑖 = (𝑎𝑋𝑖 + 𝑏𝑌𝑖)/𝑡+𝑖. Greenland’s estimator is defined as: 
𝜃𝑑,𝑋𝑌 =
𝐿𝑋+ − 𝐿𝑌+
𝑇𝑑
   (1) 
where 𝐿𝑋+ = ∑ 𝐿𝑋𝐽
𝑇𝑑
𝐽=1 . This estimator incorporates all data from each (𝑇𝑑 × 2) table. As an example, 
for the case of three treatments XYZ, 𝜃𝑑,𝑋𝑌 = (2𝐿𝑋𝑌 + (𝐿𝑋𝑍 − 𝐿𝑌𝑍))/3. 
The variance of 𝐿𝑋𝑌 is 𝑣𝑎𝑟(𝐿𝑋𝑌) = 𝑈𝑋𝑌𝑌, where 
𝑈𝑋𝑌𝑌 =
∑ 𝑐𝑋𝑌𝑖𝑤𝑋𝑌𝑖
𝑆𝑑
𝑖=1
2𝐶𝑋𝑌
2 +
∑ 𝑐𝑋𝑌𝑖𝑤𝑌𝑋𝑖 + 𝑐𝑌𝑋𝑖𝑤𝑋𝑌𝑖
𝑆𝑑
𝑖=1
2𝐶𝑋𝑌𝐶𝑌𝑋
+
∑ 𝑐𝑌𝑋𝑖𝑤𝑌𝑋𝑖
𝑆𝑑
𝑖=1
2𝐶𝑌𝑋
2  
(2) 
Note that 𝑈𝑋𝑌𝑌 = 𝑈𝑌𝑋𝑋, and thus 𝑣𝑎𝑟(𝐿𝑋𝑌) = 𝑣𝑎𝑟(𝐿𝑌𝑋). The covariance of 𝐿𝑋𝑌 and 𝐿𝑋𝑍, when 𝑋 ≠
𝑌 ≠ 𝑍 ≠ 𝑋 is given by 
𝑈𝑋𝑌𝑍 =
∑ 𝑎𝑋𝑖𝑏𝑌𝑖𝑏𝑍𝑖/𝑡+𝑖
2𝑆𝑑
𝑖=1
3𝐶𝑋𝑌𝐶𝑋𝑍
+
∑ 𝑡𝑋𝑖𝑏𝑌𝑖𝑎𝑍𝑖/𝑡+𝑖
2𝑆𝑑
𝑖=1
3𝐶𝑋𝑌𝐶𝑍𝑋
+
∑ 𝑡𝑋𝑖𝑎𝑌𝑖𝑏𝑍𝑖/𝑡+𝑖
2𝑆𝑑
𝑖=1
3𝐶𝑌𝑋𝐶𝑋𝑍
 
+
∑ 𝑏𝑋𝑖𝑎𝑌𝑖𝑎𝑍𝑖/𝑡+𝑖
2𝑆𝑑
𝑖=1
3𝐶𝑌𝑋𝐶𝑍𝑋
 
(3) 
All elements of 𝑈𝑋𝑌𝑍 for which 𝑋 = 𝑌 or 𝑋 = 𝑍 are set to zero.  Following Greenland’s notation, let us 
also define 𝑈𝑋𝑋
+ = 𝑈𝑋++ = ∑ 𝑈𝑋𝑌𝑍𝑌,𝑍  and 𝑈𝑋𝑌
+ = ∑ (𝑈𝐽𝑋𝑌 − 𝑈𝑋𝑌𝐽 − 𝑈𝑌𝑋𝐽)𝐽 + 𝑈𝑋𝑌𝑌 , 𝑋 ≠ 𝑌. Using 
these two definitions, the variance of 𝜃𝑑,𝑋𝑌 is: 
𝑣𝑎𝑟(𝜃𝑑,𝑋𝑌) =
𝑈𝑋++ − 2𝑈𝑋𝑌
+ + 𝑈𝑌++
𝑇𝑑
2   
(4) 
The covariance between two estimates 𝜃𝑑,𝑋𝑌, 𝜃𝑑,𝑋𝑍 is 
𝑐𝑜𝑣(𝜃𝑑,𝑋𝑌, 𝜃𝑑,𝑋𝑍) =
𝑈𝑋𝑋
+ − 𝑈𝑋𝑍
+ − 𝑈𝑌𝑋
+ + 𝑈𝑌𝑍
+
𝑇𝑑
2   
(5) 
More generally, the covariance between 𝜃𝑑,𝑋𝑌 and 𝜃𝑑,𝑊𝑍 is 
𝑐𝑜𝑣(𝜃𝑑,𝑋𝑌, 𝜃𝑑,𝑊𝑍) =
𝑈𝑋𝑊
+ − 𝑈𝑋𝑍
+ − 𝑈𝑌𝑊
+ + 𝑈𝑌𝑍
+
𝑇𝑑
2   
(6) 
Equations (1), (4) and (5) can be used to estimate ?̂?𝒅 and 𝑽(𝑑), and consequently 𝜽 and 𝑽. 
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Stage 3: synthesis of direct MH odds-ratios across designs assuming consistency 
In this stage we start by arbitrarily defining a reference treatment for the network. All treatment 
contrasts versus this reference treatment are the basic parameters of the NMA model. Without loss in 
generality let us define X to be the reference treatment in the network. Then the relative effects 𝛿𝑋𝑌, 
𝛿𝑋𝑍, … are the basic parameters of the model. All other relative effects, the functional parameters, can 
be calculated as linear combinations of the basic parameters, e.g. 𝛿𝛶𝛧 = 𝛿𝛸𝛧 − 𝛿𝛸𝛶 . If the dataset 
includes a total of 𝑇 treatments, then there are 𝑇(𝑇 − 1)/2 different treatment contrasts, which can be 
grouped in a vector 𝜹. From these contrasts, 𝑇 − 1 are the basic parameters (𝜹𝒃𝒂𝒔𝒊𝒄) and the rest are 
functional. Following Lu et al. 25 we can write 𝜹 = 𝑯𝜹𝒃𝒂𝒔𝒊𝒄. Matrix 𝑯 has elements 1, 0 and -1 and 
maps the basic parameters into all possible treatment comparisons in the network. 𝑯 has dimensions 
𝑇(𝑇−1)
2
× (𝑇 − 1). 
Next, we need to define the design matrix 𝑿. This is a matrix with dimensions ∑ (𝑇𝑑 − 1)𝑑 ×
(𝑇 − 1), which describes which treatments are being compared in each design and maps the 
corresponding comparison into the basic parameters.  For additional details on how to setup 𝑿 we refer 
our readers to Lu et al., Section 3.2.1 25. 
The weighted least squares NMA estimates for the basic parameters are given by ?̂?𝒃𝒂𝒔𝒊𝒄 =
(𝑿𝑻𝑽−𝟏𝑿)
−𝟏
𝑿𝑻𝑽−𝟏𝜽 30. The corresponding variance-covariance matrix is given by 𝐶𝑜𝑣(𝜹𝒃𝒂𝒔𝒊𝒄) =
(𝑿𝑻𝑽−𝟏𝑿)
−𝟏
. Finally, the NMA estimates for all treatment effects is given by 25: 
?̂? = 𝑯(𝑿𝑻𝑽−𝟏𝑿)
−𝟏
𝑿𝑻𝑽−𝟏𝜽   (7) 
with a variance-covariance matrix equal to 
𝐶𝑜𝑣(?̂?) = 𝑯(𝑿𝑻𝑽−𝟏𝑿)
−𝟏
𝑯𝑻 (8) 
3.2 Statistical evaluation of the consistency assumption in MH-NMA  
Consistency refers to the (statistical) agreement between the various sources of information in 
NMA24,31. We employ two approaches for assessing consistency: the first is a global approach (in the 
whole network), and the second is local (corresponding to each design).  
The global method is based on a generalized Cochran’s Q statistic, calculated for the whole network 
as 𝑄𝑖𝑛𝑐 = (𝜽  − 𝑿 ?̂?𝒃𝒂𝒔𝒊𝒄)
′
𝑽−𝟏(𝜽  − 𝑿 ?̂?𝒃𝒂𝒔𝒊𝒄)
32. Under the null hypothesis of consistency, the 𝑄𝑖𝑛𝑐 
statistic follows a chi-squared distribution with ∑ (𝑇𝑑 − 1)𝑑 − 𝑇 + 1 degrees of freedom, where 𝑇 
corresponds to the total number of treatments in the network. This statistic can be used to assess 
inconsistency in the whole network.  
In order to identify local inconsistency in the network, we propose a new approach, which shares 
similarities with the so-called “separate indirect from direct evidence” (SIDE) or “node-splitting” 
approach 33. In the SIDE approach the focus is on one pairwise comparison at a time, e.g. XY. Following 
this approach, if there are only two-arm (and no multi-arm) studies comparing X and Y we remove them 
from the network, and we use them to perform a pairwise meta-analysis. This provides a direct estimate 
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of the relative treatment effects of X vs. Y.  We then perform a NMA on the remaining studies, which 
provides an indirect estimate for X vs Y. The indirect and direct relative treatments effects are 
subsequently compared. If there are multi-arm studies in the network that compare X and Y, this 
approach splits only the corresponding direct estimate. E.g. if there is a three-arm study XYZ, this 
approach uses the XY estimate in the pairwise meta-analysis of direct effects, and the XZ and YZ 
estimates in the NMA that estimates the indirect effects. 
Although this method works well when all studies are two-arm, it runs into problems for the case 
when there are multi-arm studies in the network. In the example, the removed XY direct estimate from 
the multi-arm study will always agree with the indirect estimate obtained from the XZ and ZY estimates 
of the same study. This might dilute the evidence of inconsistency from the rest of the network. In 
addition, different choices of the baseline treatment in each study may lead to different estimates 
regarding the difference between direct and indirect evidence and some practical approaches have been 
suggested, e.g. see the documentation in the network34 command in Stata.  
An adaptation that can overcome this problem is to “Separate Indirect from Direct Design Evidence” 
(SIDDE). Focusing again on XY, we remove all studies that compare these two treatments, both two-
arm and multi-arm. Thus, all XY, XYZ, XYZW etc. studies are excluded from the network. The rest of 
the estimating procedure is the same as in the standard SIDE approach, i.e. we use the excluded studies 
to estimate the XY effects directly, and the rest of the network to estimate them indirectly. Note that the 
SIDDE approach shares some similarities with the net heat plot for detecting inconsistency, proposed 
by Krahn et al.32 Also note that using this approach we can only estimate inconsistency for treatment 
comparisons for which there is both direct and indirect evidence. 
3.3 Software for fitting MH-NMA 
We developed a function, netmetabin, which is included in the netmeta package 35 in R36. This 
function can be used to fit the MH-NMA method presented above. It can also fit NMA with a non-
central hypergeometric likelihood using the Breslow approximation, as proposed by Stijnen et al. 19. 
This approximation is valid when the total number of events is small relative to the group sizes. In that 
case the non-central hypergeometric distribution can be approximated by a binomial distribution37. We 
will refer to this approach as NCH-NMA. We have also implemented the SIDDE approach to 
inconsistency in the (existing) netsplit function of R package netmeta. 
On a technical note, following section 3.1, and more specifically the discussion in step (iii) of Stage 
1, the default of netmetabin when fitting MH-NMA does not perform any continuity correction when 
there are designs in which some of the treatment arms had no events. Instead, the arms are excluded 
from the network. However, the user can override this default by setting argument cc.pooled to TRUE 
and specify a fixed value for the continuity correction (argument incr). Note that NCH-NMA can be 
used in these scenarios without having to remove treatment arms or to use continuity corrections, as 
long as there are events for all the treatments in the network, irrespective of design.  
9 
 
4 Clinical examples 
4.1 Fitting details  
We compared the results from our MH-NMA method to three alternative approaches. First, we fitted 
NCH-NMA, using the R fucntion netmetabin. Second, we fitted a common-effects NMA with the 
usual, inverse-variance approach 38, also using netmetabin. We will term this method IV-NMA. In 
order to use this approach we employed a 0.5 continuity correction in studies with zero events in one or 
more treatment arms. All-zero studies were removed from the dataset. Third, we fitted a common-effect 
Bayesian NMA model with a binomial likelihood. The Bayesian model was fitted in OpenBUGS 39. For 
all model parameters, i.e. the baseline risk in each study and the true log-odds ratio, we used ‘vague’ 
prior distributions, 𝑁(0, 𝜎2 = 100). We ran 2 chains in parallel, performed 100,000 iterations, and 
discarded the first 20,000 samples of each chain. We checked convergence using the Brooks-Gelman-
Rubin criterion40. The code we used for fitting all methods is provided in the Appendix. 
4.2 Inhaled medications for patients with chronic obstructive pulmonary disease 
Results are shown in the upper part of Table 2. We also fitted random-effects IV-NMA, but between-
study variance (𝜏2) was estimated to be zero and thus results were identical to the common-effects IV-
NMA.  
It is clear that all methods give almost identical results. This is due to the fact that even though the 
event was relatively rare, there were many large studies in the network: the average sample size in the 
studies was 1280 patients. This resulted in many of the studies having enough events to adequately allow 
all methods to estimate relative treatment effects between the treatments in the network.  
Regarding inconsistency, the 𝑄𝑖𝑛𝑐 statistic was found to be 8.35 (9 degrees of freedom), 
corresponding to a p-value of 0.50, thus showing no evidence of global network inconsistency. The 
SIDDE approach to local inconsistency identified three treatment comparisons that showed some 
disagreement between direct and indirect estimates; LABA vs. LABA-ICS, LABA vs. TIO-HH and 
LABA-ICS vs. TIO-HH (p-values 0.02, 0.06 and 0.08 respectively). This in turn might call for a closer 
examination of the studies that contribute to these particular comparisons, to check for breaches in the 
transitivity assumption or the appropriateness of the assumption of homogeneity. More specifically, 
there are two studies comparing LABA vs. TIO-HH, which also contribute to the indirect evidence for 
LABA vs. LABA-ICS and LABA vs. TIO-HH. These studies may warrant further investigation.  
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Table 2. Comparison of four common-effects methods to estimate summary odds ratios in two previously 
published networks 22,23. Treatment abbreviations as given in Figure 1. MH-NMA: Mantel-Haenszel network 
meta-analysis. IV-NMA: inverse-variance network meta-analysis. NCH-NMA: non-central hypergeometric 
network meta-analysis. An odds ratio larger than 1 favours placebo in the COPD network, and control/placebo 
in the liver transplantation network 
 
4.3 Methods to decrease blood loss and blood transfusion requirements for patients 
with liver transplantation 
Results are shown in the lower part of Table 2. As in the previous example, we also fitted a random-
effects IV-NMA, but heterogeneity (𝜏2) was estimated to be zero. Thus, results from this method were 
identical to the common-effects IV-NMA shown in Table 2. 
In contrast to the first example, there are differences between the approaches. The data that we 
imputed using the continuity correction accounted for almost 20% of the total events included in the IV-
NMA. Thus, results will be strongly influenced by the imputed data, and the method cannot be trusted 
to give reliable results3. The Bayesian model might also be problematic, because the prior distributions 
used for the models’ parameters, although chosen to be “uninformative” or “vague”, might have a strong 
effect on results20. In this example, if we switch the prior distributions for the model parameters to 
𝑈(−5,5), we get quite different estimates. E.g. for rFVIIa vs. placebo the point estimate [95% Credible 
Interval, CrI] changes from 1.58 [0.37; 10.42] to 1.11 [0.32; 3.75]. Thus, in this example, given that 
 
Treatment  MH-NMA NCH-NMA IV-NMA 
Bayesian NMA 
binomial likelihood 
Inhaled medications for 
patients with chronic 
obstructive pulmonary 
disease (COPD) 22 
Mortality odds ratios 
compared to placebo 
[95% Confidence / 
Credible Intervals] 
ICS 
1.03 
[0.88; 1.21] 
1.02 
[0.88; 1.19] 
1.02 
[0.86; 1.19] 
1.03 
[0.88, 1.21] 
LABA 
0.93 
[0.79; 1.08] 
0.94 
[0.81; 1.09] 
0.93 
[0.79; 1.08] 
0.93 
[0.79; 1.09] 
LABA-ICS 
0.79 
[0.67; 0.94] 
0.81 
[0.69, 0.95] 
0.78 
[0.66; 0.93] 
0.80 
[0.67, 0.95] 
TIO-HH 
0.92 
[0.81; 1.05] 
0.93 
[0.82; 1.05] 
0.92 
[0.81; 1.04] 
0.92 
[0.81; 1.04] 
TIO-SMI 
1.52 
[1.05; 2.19] 
1.50 
[1.05; 2.14] 
1.50 
[1.04; 2.17] 
1.52 
[1.06; 2.19] 
Methods to decrease 
blood loss and blood 
transfusion 
requirements for 
patients with liver 
transplantation 23 
Mortality odds ratios 
compared to 
control/placebo 
[95% Confidence / 
Credible Intervals] 
Aprotonin 
0.36 
[0.13; 0.99] 
0.36 
[0.14; 0.96] 
0.40 
[0.15; 1.08] 
0.32 
[0.11; 0.87] 
EACA 
0.74 
[0.14; 3.89] 
0.77 
[0.16; 3.77] 
0.81 
[0.16; 4.26] 
0.71 
[0.12; 3.92] 
rFVIIa 
1.54 
[0.31; 7.53] 
1.51 
[0.32; 7.17] 
1.54 
[0.31; 7.53] 
1.58 
[0.37; 10.42] 
Tranexamic 
acid 
0.77 
[0.23; 2.61] 
0.81 
[0.27; 2.43] 
0.90 
[0.28; 2.96] 
0.76 
[0.24; 2.54] 
Antithrombin 
III 
- - 
0.21 
[0.01; 4.89] 
0.0003 
[0.00; 0.72] 
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there is no available external information to feed in the Bayesian models in the form of informative 
priors, our MH-NMA or the NCH-NMA might be the best option for analysis.  
Note that Antithrombin III does not feature in the results of MH-NMA and NCH-NMA in Table 2. 
This is because this treatment was only included in one two-arm study with zero events in one of each 
arms, and such designs are removed from these two methods (unless a continuity correction is used). 
This highlights one of the potential disadvantages of the frequentist approaches, as opposed to the 
Bayesian ones. Based on the findings of the Bayesian model with the binomial likelihood presented in 
Table 2, one might argue that there is enough evidence that Antithrombin III is safer than control/placebo 
(estimated odds ratio 0.0003, with a 95% CrI 0.00 to 0.72). However, as discussed above, such results 
are heavily dependent on the prior. Using a 𝑈(−5,5) prior, the odds ratio estimate is 0.02 [0.0002; 1.36], 
shedding doubts about the effectiveness of this intervention.  
No evidence of global inconsistency was found for this network. 𝑄𝑖𝑛𝑐 was 1.88 (2 degrees of 
freedom, for a p-value of 0.39). The SIDDE approach did not provide any evidence for inconsistency 
either. Results are shown in Table 3.  
5 Simulations 
In this section we describe a simulation study to compare our MH-NMA method with other 
methods for NMA. Our aim was to assess the performance of the competing approaches under different 
scenarios, by varying factors regarding data availability, heterogeneity, network structure, event rates 
etc. Our simulation study follows the structure proposed by Morris et al. 41. 
 
5.1 Data generating mechanisms 
We explored a total of 20 scenarios. In all scenarios we generated only fully connected networks, 
with at least two studies for every treatment comparison, in order to avoid having simulated datasets 
that result in disconnected networks when the assumed event rate is very low. For each scenario we 
independently generated 1000 datasets. The simulated a number of studies varied across scenarios (see 
details below). In all studies we assumed equal number of patients per treatment arm. The number of 
patients per treatment arm was generated separately for each study. 
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Inhaled medications for patients with chronic obstructive pulmonary disease 
 Q df p-value 
Global inconsistency in the network 8.35 9 0.50 
Inconsistency estimated using the SIDDE 
approach 
Ratio of odd ratios  
(direct over indirect odds ratios) 
p-value 
ICS:LABA 1.29 [0.77; 2.17] 0.34 
ICS: LABA-ICS 1.03 [0.58; 1.85] 0.92 
LABA : LABA-ICS 0.47 [0.24; 0.89] 0.02 
LABA : Placebo 0.88 [0.60; 1.29] 0.52 
LABA:TIO-HH 1.45 [0.98; 2.16] 0.06 
LABA-ICS:Placebo 1.10 [0.69; 1.75] 0.78 
LABA-ICS:TIO-HH 0.59 [0.33; 1.06] 0.08 
Placebo:TIO-HH 1.05 [0.74; 1.50] 0.79 
Methods to decrease blood loss and blood transfusion requirements for patients with 
liver transplantation 
 Q df p-value 
Global inconsistency in the network 1.88 2 0.39 
Inconsistency estimated using the SIDDE 
approach 
Ratio of odd ratios  
(direct over indirect odds ratios) 
p-value 
Aprotonin:Control/Placebo 5.97 [0.36; 98.99] 0.21 
Aprotonin:Tranexamic acid 0.17 [0.01;  2.78] 0.21 
Control/Placebo:Tranexamic acid 0.16 [0.01;  2.62] 0.20 
Table 3: Results from the assessment of inconsistency in the two clinical examples 
In scenarios 1-16 we generated only two-arm studies. The number of patients per treatment arm 
was simulated by drawing from a uniform distribution 𝑈(30,60), and then rounding to a whole number. 
For each study we generated a study baseline risk; that is the risk of event of patients receiving a 
reference treatment (treatment 1) irrespective of whether this was evaluated in the study. The study 
baseline risk was generated from a uniform distribution with parameters that varied by scenario (details 
below). The underlying true log-odds ratios (logORs) of each treatment vs. treatment 1 were fixed at 
equal intervals between 0 and 1. For example in a scenario with 5 treatments, the true logORs for 
treatments 2, 3, 4 and 5 vs. treatment 1 were set to 0.25, 0.50, 0.75 and 1.00 respectively. For scenarios 
assuming homogeneity, we used these logORs together with the simulated, study-specific baseline risk, 
to calculate the probability of an event in each study treatment arm. The number of events in a study 
arm was generated from a Binomial distribution, using the (study- and treatment-specific) probability 
of an event, as well as the study-specific number of patients per treatment arm. For scenarios that assume 
heterogeneity, we set a common standard deviation of the random effects (𝜏) for all treatment 
comparisons in the network. For these scenarios, we simulated study-specific logORs, accounting for 𝜏, 
i.e. by drawing from a normal distribution with a mean determined by the comparison, and standard 
deviation equal to 𝜏; otherwise the procedure was unchanged In scenarios 1-16 we explored the 
following settings: 
 number of treatments in the network: 5 or 8. 
 number per studies per treatment comparison: 2 or 4.  
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 standard deviation of random effects: 𝜏 = 0 (homogeneous treatment effects) and 𝜏 = 0.1 
(heterogeneous treatment effects).  
 baseline event rate in each study: generated after drawing from 𝑈(0.03,0.05) or 𝑈(0.05,0.10) 
In scenarios 17-20 we considered more complicated situations that included multi-arm studies, 
large sample sizes and event rates, or very small event rates. More specifically: 
 In Scenario 17 we assumed 3 treatments in the network populated by 3-arm studies and no 
heterogeneity. 
 In Scenario 18 we assumed more patients per treatment arm (𝑈(100,200)) and large event 
rates (baseline risk 𝑈(0.30,0.50)), only two-arm studies and no heterogeneity. 
 Scenario 19 was equivalent with Scenario 18 but with heterogeneity 𝜏 = 0.1. 
 In Scenario 20 we assumed three 3 treatments in the network, and very low baseline event 
rates from 𝑈(0.01,0.02)). We assumed only two-arm studies and no heterogeneity. 
Table 4 provides an overview of the data generating mechanism in each scenario.  
 
# 
Treatments 
in the 
network 
Patients per 
treatment arm 
Number or 
studies per 
comparison 
Heterogeneity 
standard 
deviation (τ) 
Baseline risk 
1 5 30 to 60 2 0 3-5% 
2 5 30 to 60 2 0.1 3-5% 
3 5 30 to 60 2 0 5-10% 
4 5 30 to 60 2 0.1 5-10% 
5 5 30 to 60 4 0 3-5% 
6 5 30 to 60 4 0.1 3-5% 
7 5 30 to 60 4 0 5-10% 
8 5 30 to 60 4 0.1 5-10% 
9 8 30 to 60 2 0 3-5% 
10 8 30 to 60 2 0.1 3-5% 
11 8 30 to 60 2 0 5-10% 
12 8 30 to 60 2 0.1 5-10% 
13 8 30 to 60 4 0 3-5% 
14 8 30 to 60 4 0.1 3-5% 
15 8 30 to 60 4 0 5-10% 
16 8 30 to 60 4 0.1 5-10% 
17 3 30 to 60 8 0 1-10% 
18 5 100 to 200 2 0 30-50% 
19 5 100 to 200 2 0.1 30-50% 
20 3 30 to 60 8 0 1-2% 
Table 4: Overview of the scenarios we explored in our simulations. For each scenario we generated 
1000 independent datasets. Rows shaded grey correspond to scenarios where we assumed 
heterogeneity. 
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5.2 Methods compared, estimands and measures of performance 
Each of the 1000 datasets of each scenario was analysed using four different approaches: (i) 
common-effects IV-NMA with 0.5 continuity correction; (ii) random effects IV-NMA with 0.5 
continuity correction; (iii) MH-NMA without continuity correction; and (iv) NHC-NMA without 
continuity correction. We did not consider Bayesian models, as for rare outcomes the performance of a 
Bayesian model might heavily depend on the prior distributions used (see Section 4.3 for an illustration).  
The target estimands of our analyses were the logORs between treatments versus treatment 1 (i.e. 
the basic parameters). The performance of each method was assessed by comparing the estimated 
logORs with their corresponding true values. We calculated the mean bias, defined as the mean 
difference between the estimated and the true logORs, the mean absolute bias, and the mean coverage 
in each scenario, as the percent of 95% confidence intervals that included the corresponding true logOR. 
All analyses were performed in R using the netmeta package. The codes used for our simulations can 
be found in https://github.com/esm-ispm-unibe-ch-REPRODUCIBLE/MH_NMA. 
5.3 Results from simulations 
We present the results of the simulation study in Table 5.  
IV-FE and IV-RE gave almost identical results for all scenarios. This is because when event rates 
are low, it is difficult to estimate 𝜏, and the method of moments estimates ?̂? = 0. In scenarios 1 to 16, 
MH-NMA always provided the least biased estimates, followed closely by NCH, which had identical 
mean bias in 4 of 16 scenarios. In most of these scenarios, NCH had a coverage slightly closer to the 
nominal level (95%) than MH. The IV method had the worst performance both in terms of bias and 
coverage, although in some cases differences were trivial. Also, simulating heterogeneity led to only a 
marginal increase of bias in the estimates of MH and NCH.  
 In scenario 17, with multi-arm studies only, MH gave again the least biased results, with similar 
coverage with NCH. Scenarios 18 and 19 assumed higher frequencies of events and NCH performed 
very poorly due to using the Breslow approximation, which is only valid for rare events (see Section 
3.3). In Scenario 20, with very low event rates, the IV method showed large biases, while MH and NCH 
were practically unbiased. NCH again provided a slightly better coverage, i.e. slightly closer to the 
nominal level.  
Note that in Table 5 we show the values of mean bias, absolute bias and coverage of all estimated 
logORs, i.e. we average over all basic parameters of each scenario. Thus, the values presented in Table 
5 could be further split, for each basic parameter in each scenario. For example, in Scenario 1, where 
we assumed 5 treatments (4 basic parameters), the true values of the logORs were (0.25, 0.50, 0.75, 
1.00). The corresponding mean biases across the four basic parameters were (-0.04, -0.07, -0.09, -0.11), 
while the mean bias for the common-effects IV-NMA across all basic parameters was -0.08 (as shown 
in Table 5 ). Similarly, for MH the mean bias across all basic parameters was -0.05, and the biases of 
the basic parameter were (-0.04, -0.05, -0.05, -0.06) respectively. 
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Overall, we conclude that IV-NMA with a continuity correction is a suboptimal choice, when 
events are rare. MH-NMA and NCH-NMA with the Breslow approximation performed comparably in 
most scenarios. Due to the fact that this approximation is inadequate for large event rates or when there 
is a mixture of low and high event rates across the studies, we recommend the use of MH-NMA. For the 
case when all studies show low event rates, NCH-NMA might offer a slight advantage over MH-NMA 
in terms of coverage. Readers should keep in mind, however, that in our simulations we did not explore 
the performance of the full NCH-NMA method (i.e. including random effects, without the Breslow 
approximation). See also the Discussion section, regarding possible areas of future research.  
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Scenario 
IV - FIXED IV - RANDOM MH-NMA NCH-NMA 
Mean 
bias 
Mean 
absolute 
bias 
Coverage 
Mean 
bias 
Mean 
absolute 
bias 
Coverage 
Mean 
bias 
Mean 
absolute 
bias 
Coverage 
Mean 
bias 
Mean 
absolute 
bias 
Coverage 
1 -0.08 0.30 97.8% -0.07 0.30 97.9% -0.05 0.31 97.4% -0.05 0.31 96.4% 
2 -0.07 0.31 97.6% -0.07 0.31 97.6% -0.05 0.32 96.8% -0.05 0.32 96.0% 
3 -0.04 0.24 97.6% -0.04 0.23 97.8% -0.01 0.24 96.8% -0.06 0.23 95.8% 
4 -0.04 0.24 96.7% -0.03 0.24 97.2% -0.01 0.25 95.7% -0.06 0.24 95.2% 
5 -0.08 0.22 97.2% -0.08 0.22 97.2% 0.00 0.23 96.0% -0.02 0.22 95.1% 
6 -0.09 0.22 97.4% -0.08 0.22 97.4% -0.01 0.23 96.2% -0.03 0.22 95.5% 
7 -0.04 0.17 96.5% -0.04 0.17 96.8% 0.00 0.17 95.6% -0.06 0.17 94.0% 
8 -0.05 0.17 96.6% -0.05 0.17 96.9% -0.01 0.18 95.3% -0.07 0.17 94.2% 
9 -0.07 0.24 97.3% -0.07 0.24 97.3% -0.05 0.26 96.8% -0.05 0.25 95.8% 
10 -0.08 0.24 97.5% -0.07 0.24 97.5% -0.05 0.25 96.6% -0.05 0.25 95.8% 
11 -0.04 0.19 96.5% -0.04 0.19 96.7% -0.02 0.19 95.9% -0.06 0.19 95.0% 
12 -0.04 0.19 96.7% -0.04 0.19 96.9% -0.02 0.20 95.9% -0.06 0.19 94.8% 
13 -0.07 0.18 96.8% -0.07 0.18 96.9% 0.00 0.18 96.1% -0.02 0.18 95.3% 
14 -0.08 0.18 97.1% -0.08 0.18 97.1% -0.02 0.18 95.8% -0.04 0.18 95.0% 
15 -0.04 0.14 96.5% -0.04 0.14 96.6% 0.00 0.14 95.6% -0.05 0.14 94.2% 
16 -0.05 0.14 96.2% -0.05 0.14 96.3% -0.01 0.14 95.4% -0.07 0.14 93.3% 
17 -0.06 0.23 96.2% -0.06 0.23 96.6% 0.03 0.25 94.3% -0.05 0.23 94.5% 
18 0.00 0.08 95.7% 0.00 0.08 96.6% 0.00 0.08 95.7% -0.31 0.31 21.0% 
19 0.00 0.09 92.5% 0.00 0.09 94.6% 0.00 0.09 92.4% -0.31 0.31 21.0% 
20 -0.18 0.26 97.1% -0.18 0.26 97.1% 0.01 0.29 96.2% 0.00 0.29 95.5% 
Table 5: Overview of simulation results. Methods’ abbreviations as per Table 2. Rows shaded grey correspond to scenarios where we assumed heterogeneity. 
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6 Discussion 
We presented a method for NMA of binary outcomes, using a generalized version of the Mantel-
Haenszel approach to pairwise meta-analysis. The method synthesises odds ratios and it does not rely 
on the normal approximation to estimate study variances. It allows the inclusion of information from 
studies with zero events in some, but not all, treatment arms, without a continuity correction.  
One limitation of our method is that it is limited to odds-ratios. An extension to risk ratios might 
be interesting to pursue in future work. However, for the case of sparse data, the difference between 
odds and risks becomes negligible, and thus odds ratios can be interpreted as risk ratios for practical 
purposes. Another limitation of our method is that it can only be used to perform a common-effects 
network meta-analysis. However, when the event rate is low, the estimation of heterogeneity in a 
frequentist setting can be difficult42. In both clinical applications we presented in this paper the 
heterogeneity standard deviation was estimated to be zero using the method of moments43, and the IV-
NMA analyses were performed under a common-effect assumption. A similar picture was seen in our 
simulation study: when events were rare, the random-effects IV-NMA gave on average almost identical 
results to the fixed-effects IV-NMA. Thus, although our MH-NMA method’s inability to include 
random effects is in theory a disadvantage, for the case of rare events the IV-NMA method might in 
practice be also limited to the common-effects approach. Note that the Cochrane Handbook suggests 
that incorporation of heterogeneity should be a secondary consideration when attempting to estimate 
treatment effects from sparse data44. 
The fact that the MH-NMA method does not account for heterogeneity suggests that the results 
from the global test or the SIDDE method to assess inconsistency should be interpreted with caution. If 
heterogeneity is present in the form of within-design variability, then ignoring it when estimating the 
variance of the direct summary odds-ratios might contribute to inconsistency. Hence, important 
inconsistency in the data should challenge the assumption of the homogeneity that underlines the model. 
Researchers should also keep in mind that tests for inconsistency have in general low power45. 
Consequently, lack of evidence for inconsistency should not be interpreted as evidence for consistency. 
Careful consideration of the study inclusion criteria and evaluation of their similarity with respect to 
effect modifiers should always take place to ensure that the network has low risk of intransitivity16. 
The majority of published NMA are fitted within a Bayesian framework18,46. In this case, the exact 
binomial likelihood for the data can be employed without requiring any ‘correction’ for zero events in 
study arms. However, similar to other Bayesian analyses, the sparser the data, the bigger the influence 
of the prior distributions on the posterior estimates of the model. Different “uninformative” or “vague” 
prior distributions may lead to different estimated effects sizes. The impact is generally larger for scale 
parameters (e.g. the variance of random effects) than location parameters (e.g. the true underlying effect 
size)20. The problem can be mitigated with the use of informative priors for at least some of the model 
parameters, and in particular for heterogeneity47. As illustrated in the liver transplant example in Section 
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4.3, the choice of priors for the location parameters can have a strong impact on some of the estimated 
effect sizes in a NMA. Thus, unless meta-analysts have at their disposal high-quality external 
information for all model parameters, results from applying Bayesian methods may not be robust.  
As illustrated in the chronic obstructive pulmonary disease example, the IV-NMA method might 
be a reasonable frequentist alternative when there are several studies with relatively large numbers of 
events in the dataset. Conversely, in cases where the IV-NMA method requires the imputation of a large 
amount of data (as in the liver transplant example), MH-NMA might be a better option for a frequentist 
analysis. Stijnen et al. proposed an alternative frequentist approach to NMA, that can be used when the 
outcome is rare19. This uses an exact conditional likelihood, i.e. it models the likelihood of events in 
each study arm given the total number of events in the study using the non-central hypergeometric 
distribution. For both examples presented in this paper MH-NMA and the common-effect non-central 
hypergeometric method gave similar results. However, the two methods make different distributional 
assumptions about the observed data (i.e. the approach by Stijnen et al. implements a non-central 
hypergeometric distribution) and might provide different estimates in other cases, especially if the 
random effects version of that approach is used (but we have not yet implemented this option in 
netmeta).  
In our simulation study we compared the performance of MH-NMA with the IV-NMA method 
(both fixed- and random-effects IV-NMA, using a 0.5 continuity correction) and also with the fixed 
effects method proposed by Stijnen et al. (NCH-NMA), employing an approximation only valid for 
small event rates. We found that our method performed similarly to NCH-NMA in most scenarios, when 
events are rare; both methods performed better than IV-NMA. Consequently, we recommend that 
researchers perform sensitivity analyses using these two methods alongside Bayesian NMAs, to evaluate 
the robustness of conclusions5,9. The use of IV-NMA for binary outcomes should be restricted to the 
case when events are not rare.  
In order to provide recommendations regarding the optimal approach in more variable scenarios, 
future work could focus on comparing in simulations our MH-NMA model with the random-effects 
method by Stijnen et al. (without approximation) and also Bayesian NMA models with different priors. 
The different approaches could also be empirically compared in large collections of meta-analyses, to 
see if, and in which cases, there are important differences in the estimates of the different methods in 
practice. Additional simulation studies would also be needed to assess the performance of the available 
methods for assessing inconsistency. One other area of future research could be to explore different 
approaches to MH-NMA. For example, one could perform a ‘data-augmentation’ to all studies48, i.e. 
artificially impute treatment arms with zero events and zero non-events for the missing treatments of all 
studies. This would lead to all studies having the same design (comparing all treatments), and would 
render Stage 3 of Section 3.1 obsolete. However, there might be no way to check for inconsistency with 
this approach. Finally, other models currently available only for pairwise meta-analysis could also be 
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extended for the case of NMA, such as beta-binomial models6,49, the simple average estimator42 and 
others. 
In summary, our extension of the Mantel-Haenszel method to network meta-analysis offers a 
useful new approach for the synthesis of binary outcomes, especially when the events are rare, and/or 
the sample sizes of the included studies are small. Moreover, using the netmeta command in R, the 
application of our methods is straightforward in practice. 
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